DrugPatentWatch Database Preview
MAVYRET Drug Profile
When do Mavyret patents expire, and when can generic versions of Mavyret launch?
Mavyret is a drug marketed by Abbvie Inc and is included in one NDA. There are six patents protecting this drug.
This drug has three hundred and twenty-seven patent family members in forty-four countries.
The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
Summary for MAVYRET
| International Patents: | 327 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 5 |
| Drug Prices: | Drug price information for MAVYRET |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for MAVYRET |
| DailyMed Link: | MAVYRET at DailyMed |
Generic Entry Opportunity Date for MAVYRET
Generic Entry Date for MAVYRET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for MAVYRET
International Patents for MAVYRET
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | C2692346 | ➤ Try a Free Trial |
| Japan | 2014144973 | ➤ Try a Free Trial |
| China | 103596941 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2012116257 | ➤ Try a Free Trial |
| Dominican Republic | P2013000062 | ➤ Try a Free Trial |
| Hungary | E028825 | ➤ Try a Free Trial |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for MAVYRET
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2368890 | CR 2015 00015 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150119 |
| 2618831 | 17C1039 | France | ➤ Try a Free Trial | PRODUCT NAME: GLECAPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN ESTER DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
| 2618831 | 300 50016-2017 | Slovakia | ➤ Try a Free Trial | PRODUCT NAME: GLECAPREVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
| 2692346 | 2017/046 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2618831 | 1790051-5 | Sweden | ➤ Try a Free Trial | PRODUCT NAME: GLECAPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/17/1213 20170728 |
| 2368890 | PA2015012 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIRUM; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
